Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries

Jahr

2026

Autoren

de Keijzer C, E JY, Yang Q, Gitonga R, Hiller D, Jurgensen S, Salloum N, Cunha-Santos J, Hoogewys-Cynober E, Vinet L, Chirieac M, Benzerdjeb H, Thoene D, Ziemssen T, Drahota J, Horáková D, Brown W, Hobart J, Robertson NP, Hakkarainen KM, Sinnott SJ.

Verlag

Ther Adv Neurol Disord. 2026 May 21;19:17562864261444676.

Link

https://doi.org/10.1177/17562864261444676

Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries

Beyond B Cell Depletion: Adhesion and Activation Network Remodeling During Repeated Intravenous Anti-CD20 Therapy in Multiple Sclerosis

Jump assessment on a force plate—an approach to quantify subtle lower limb neuromuscular deficits in people with multiple sclerosis

Nutritional state-dependent changes in subcortical limbic structures in anorexia nervosa are linked to leptin, ghrelin, and neurofilament light

Beyond the interferon score: neurofilament light chain and glial fibrillary acidic protein capture immune-mediated neuroinjury and response to JAK inhibition in Aicardi–Goutières syndrome

Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy